Latest news with #Lurker
Reuters
21-02-2025
- Entertainment
- Reuters
Rising British star Archie Madekwe says 'Lurker' accurately explores male power dynamics
BERLIN, Feb 21 (Reuters) - Rising British star Archie Madekwe said in Berlin on Friday that the male power dynamics reflected in "Lurker", a thriller about a conniving music fan, chimed with his preparation for the role. "I was continuously surprised in my research in speaking to a lot of these male musicians, how male dominant their worlds often were," Madekwe told journalist at the Berlin Film Festival, where "Lurker" is playing in the non-competitive Special selection. The musicians created "this weird toxic masculinity world, it was interesting, those power dynamics," said Madekwe, who starred in "Gran Turismo" and also has had roles in "Saltburn" and "Midsommar". That was not his experience in the world of acting and television, said Madekwe, who was also a producer on "Lurker". In the film, a Sundance Film Festival standout, Madekwe is pop star Oliver, whose encounter with retail worker and secret fan Matthew, played by Canadian actor Theodore Pellerin, slowly develops into a struggle for power and influence. The dynamic between the main characters was drawn from first-time director Alex Russell's experiences working in Los Angeles, though not to the extremes that play out in the film, he said on Friday. However, "nothing that happens in the film is out of the realm of possibility," he added. Russell, a writer and producer on Emmy-winning shows "The Bear" and "Beef", said that shooting in LA was really important to him for the authenticity of the film. Russell said the main house in "Lurker" had since completely gone following the devastating fires in LA last month. His breakout film was critically praised after its premiere at the Sundance Film Festival last month, with The Guardian, opens new tab giving it four out of five stars and The Hollywood Reporter, opens new tab summarizing the movie as "a wicked spin on the fame game".
Yahoo
08-02-2025
- Entertainment
- Yahoo
MUBI Acquires Sundance Favorite ‘Lurker,' Sets Theatrical Release
'The Substance' distributor MUBI has acquired Sundance favorite 'Lurker' following a highly competitive bidding war and will release the movie in theaters later this year. The film will receive its international premiere at the 2025 Berlinale. The film, which made its world premiere at the Sundance Film Festival this year, tells the story of a retail employee who infiltrates the inner circle of a music artist on the verge of stardom. But, 'as he gets closer to the budding music star, access and proximity become a matter of life and death.' Writer and director Alex Russell has been part of major shows like 'Dave' and 'The Bear,' but 'Lurker' marks his feature directorial debut. 'It was already such a privilege to show our movie at Sundance last week. I'm honestly still reeling and recovering from that experience' said director Russell in an official statement. 'To have found such an ideal partner in MUBI and get the chance to bring it wider feels like an added bonus.' In her review of the film, TheWrap's Ronda Racha Penrice wrote: 'Lurker' is a deep meditation on male self-worth in the vein of Joaquin Phoenix in the 'Joker' franchise, only more realistic. While the film poses more questions than it does solutions, Russell succeeds in expanding awareness and conversation around male displacement and longing for belonging. Starring Théodore Pellerin, Archie Madekwe, Havana Rose Liu, Sunny Suljic, Zack Fox and Daniel Zolghadri, the story started as just one scene that Russell wrote during the pandemic, as he observed real-life interactions his own friends had in the music industry. 'And then COVID just kept going. So I kept writing it, and then it became a 100-page script,' Russell said at TheWrap's Sundance Studio presented by World of Hyatt. 'And here it is. Here we are.' The post MUBI Acquires Sundance Favorite 'Lurker,' Sets Theatrical Release appeared first on TheWrap.
Yahoo
06-02-2025
- Entertainment
- Yahoo
Sundance Favorite ‘Lurker' Sells to ‘The Substance' Distributor Mubi (EXCLUSIVE)
Riding momentum from its five Academy Award nominations for 'The Substance,' boutique movie distributor Mubi has picked up another buzzy indie film for the U.S. market. 'Lurker,' a tense feature about an ambitious hipster and the rising pop star he exploits for fame and community, has been snapped up by Mubi following this year's Sundance Film Festival. Screening in the fest's premiere section, Mubi took 'Lurker,' written and directed by Alex Russell, in a competitive situation for a mid-seven-figure price tag. More from Variety Barry Keoghan, Christopher Abbott Thriller 'Bring Them Down' Gets New Clip Ahead of Mubi Theatrical Release (EXCLUSIVE) 'Love, Brooklyn' Review: André Holland, Nicole Beharie and DeWanda Wise Carry a Simmering Romantic Drama 'Sunfish and Other Stories on Green Lake' Review: A Relaxing Omnibus Movie Dips Its Toe in a Small-Town Michigan Summer Exact numbers weren't disclosed but one person with knowledge of the deal told Variety that the sale represents a significant domestic theatrical release commitment from Mubi. The indie distributor previously released 'The Substance' (a negative pickup from Universal Pictures with a $15 million price tag, before factoring in marketing and awards campaign costs) and 'Decision to Leave.' Rising star Théodore Pellerin plays Matty, a lowly clerk at a high-end sneaker and apparel store in Los Angeles. When his favorite singer (Archie Madekwe of 'Saltburn') saunters in, Pellerin swings into action cozying up to the social media star. Before long, Matty installs himself in a world of hedonism and opportunity — and he can stay, as long as he manages the pecking order of the entourage and the fickle demands of celebrity. Everything that can go wrong does, taking audiences on a bleak and unsavory ride through the petty and fatal byways of modern fame. The film marks an impressive debut from writer-director Russell, who cut his teeth on the Emmy-winning Netflix series 'Beef.' Havana Rose Liu, Sunny Suljic, Zach Fox and Daniel Zolghadri star alongside Pellerin and Madekwe. WME Independent handled the sale on behalf of the filmmakers. Producers include Alex Orlovsky, Duncan Montomery, Galen Core, Francesco Melzi D'Eril, Jack Selby, Marc Marrie, Charlie McDowell, Madekwe and Olmo Schnabel. Other Sundance sales include the doc 'Perfect Neighbor' and Joel Edgerton and Felicity Jones-led novella adaptation 'Train Dreams' to Netflix, searing drama 'Sorry, Baby' to A24 and body-horror thriller 'Together' to Neon. Best of Variety New Movies Out Now in Theaters: What to See This Week Grammy Predictions, From Beyoncé to Kendrick Lamar: Who Will Win? Who Should Win? What's Coming to Netflix in February 2025
Yahoo
05-02-2025
- Business
- Yahoo
Collegium Appoints Nancy S. Lurker to its Board of Directors
STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the appointment of Nancy S. Lurker to its Board of Directors, effective February 4, 2025. 'Collegium is pleased to welcome Nancy to our Board of Directors,' said Mike Heffernan, Founder and Chairman of the Board of Collegium. 'Nancy's expertise in driving commercial growth and strategic acquisitions will be of great value to Collegium as we continue to build a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.' 'This is a pivotal and exciting time for Collegium as it embarks on a new stage of growth following its recent expansion into the neuropsychiatry market,' said Ms. Lurker. 'I look forward to collaborating with Collegium's Board to advance the Company's mission.' Ms. Lurker most recently served as President and Chief Executive Officer of EyePoint Pharmaceuticals, Inc. until 2023, when she transitioned to the role of Executive-Vice Chair of its Board of Directors. Prior to EyePoint, Ms. Lurker was President, CEO and Board Director of PDI, Inc., a Nasdaq-listed healthcare commercialization company, which sold to Publicis Health. Before joining PDI, she served as Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals and as President and CEO of ImpactRx, Inc. In addition to her Board appointments at Collegium and EyePoint, Ms. Lurker serves on the Board of Directors of Alkermes plc and Altasciences, LLC. She also serves on Advisory Boards for Novo Holdings and for Stanford Medicine's Master of Science in Translational Research and Applied Medicine program. She has previously held positions on the Boards of Cancer Treatment Centers of America, Mallinckrodt Pharmaceuticals, Auxilium Pharmaceuticals, PDI, Elan Pharmaceuticals, ConjuChem and ImpactRx. Ms. Lurker holds a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. About Collegium Pharmaceutical, Inc. Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and recently acquired Jornay PM, a treatment for ADHD, establishing a presence in neuropsychiatry. Collegium's strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium's headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company's website at Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Examples of forward-looking statements contained in this press release include, among others, statements related to expectations (financial or otherwise) and intentions, and other statements that are not historical facts. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results, performance, or achievements to differ materially from the Company's current expectations, including risks relating to, among others: unknown liabilities; risks related to future opportunities and plans for our products, including uncertainty of the expected financial performance of such products; our ability to commercialize and grow sales of our products; our ability to successfully integrate the operations of Ironshore into our organization, and realize the anticipated benefits associated with the acquisition; our ability to manage our relationships with licensors; the success of competing products that are or become available; our ability to maintain regulatory approval of our products, and any related restrictions, limitations, and/or warnings in the label of our products; the size of the markets for our products, and our ability to service those markets; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products; the costs of commercialization activities, including marketing, sales and distribution; changing market conditions for our products; the outcome of any patent infringement or other litigation that may be brought by or against us; the outcome of any governmental investigation related to our business; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and manufacture adequate supplies of commercially saleable inventory; our ability to obtain funding for our operations and business development; regulatory developments in the U.S.; our expectations regarding our ability to obtain and maintain sufficient intellectual property protection for our products; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; our customer concentration; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q and other filings with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. Investor Contact:Danielle JesseDirector, Investor Relationsir@ Media Contact:Cheryl WheelerHead of Corporate Communicationscommunications@
Yahoo
31-01-2025
- Entertainment
- Yahoo
FCC Requests Full Transcript of '60 Minutes' Interview With Harris Amid Paramount Deal Review
CBS News says it will comply with a request from the Federal Communications Commissions for a 'full unedited transcript' and feeds from its interview with Vice President Harris. 'Late Wednesday, CBS News was sent a Letter of Inquiry from the Federal Communications Commission asking for the full, unedited transcript and camera feeds from our interview with Vice President Harris which aired on October 7, 2024. We are working to comply with that inquiry as we are legally compelled to do,' CBS said in a statement. More from The Hollywood Reporter 'Lurker' Review: Théodore Pellerin and Archie Madekwe Pop the Fame Bubble in Alex Russell's Scintillating Power Play Mike White Teases a Much Darker 'White Lotus': "The Other Seasons Were a Rehearsal for This One" Irina Shayk's Go-To 'White Truffle' Face Serum Is On Sale for Just $20 The request came as the FCC reviews Paramount Global's planned merger with Skydance Media. But also comes after President Donald Trump's lawsuit against CBS concerning this interview. In the $10 million suit, Trump has alleged that the network edited the interview to try to help Harris win the election. More to come. Best of The Hollywood Reporter How the Warner Brothers Got Their Film Business Started Meet the World Builders: Hollywood's Top Physical Production Executives of 2023 Men in Blazers, Hollywood's Favorite Soccer Podcast, Aims for a Global Empire
